Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder.

In a recent study, transcranial magnetic stimulation was found to be more effective than switching to a new medication for ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

TMS has been approved for treating clinical depression in adults since 2008. Recent effectiveness data with adolescents shows ...

Depression, which doctors may call major depressive disorder, is a treatable mental ... test to see if you have it and help you manage and treat it. By far, insomnia is the most common sleep ...

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...

PTSD is a serious mental health condition marked by changes in mood, intrusive memories, avoidant behavior, and a heightened ...

Once you get treatment for mania ... While bipolar disorder can cause a depressed mood, bipolar disorder and depression have one major difference. With bipolar disorder, you might have “up ...